QuidelOrtho Corporation is a leading global provider of in vitro diagnostic solutions, formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics in 2022. The company amalgamates over 120 years of collective experience and innovation in diagnostics, focusing on developing and manufacturing cutting-edge technologies to improve patient outcomes across healthcare settings including point-of-care, clinical laboratories, and transfusion medicine.

Headquartered in San Diego, QuidelOrtho has a rich legacy of pioneering advancements in diagnostic science, including the development of the earliest lateral-flow pregnancy test strips and the first FDA-approved rapid antigen diagnostic tests for Influenza A and B. The company also introduced the first-ever product to determine Rh blood type and developed the world’s first tests for antibodies against HIV and hepatitis C.

QuidelOrtho’s innovation extends to patented dry-slide technology, which has helped reduce costs and expand the reach of in vitro diagnostic testing. The company played a significant role during the COVID-19 pandemic by developing early molecular PCR assays for SARS-CoV-2, the first FDA emergency use authorized rapid antigen test yielding results in 15 minutes, and high-volume antibody and antigen tests.

Growth has been driven by strategic acquisitions, such as Diagnostic Hybrids and assets from Alere Inc.’s Triage MeterPro line, which have expanded its product portfolio and market access. QuidelOrtho focuses on rapid diagnostics across infectious diseases, women’s health, and other critical care areas.

The company’s mission emphasizes raising diagnostic performance standards to enhance clinical decision-making and patient care worldwide, positioning it among the largest and most innovative IVD providers globally.